Vistagen Therapeutics Stock Analysis
| VTGN Stock | USD 2.81 0.10 3.44% |
VistaGen Therapeutics is undervalued with Real Value of 5.46 and Target Price of 13.0. The main objective of VistaGen Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what VistaGen Therapeutics is worth, separate from its market price. There are two main types of VistaGen Therapeutics' stock analysis: fundamental analysis and technical analysis.
The VistaGen Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. VistaGen Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. VistaGen Stock trading window is adjusted to America/New York timezone.
VistaGen |
VistaGen Stock Analysis Notes
About 53.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.04. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 1.48. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system . VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Vistagen Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. For more information please call Shawn JD at 650 577 3600 or visit https://www.vistagen.com.VistaGen Therapeutics Investment Alerts
| VistaGen Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.06 M. Net Loss for the year was (29.36 M) with profit before overhead, payroll, taxes, and interest of 698 K. | |
| VistaGen Therapeutics currently holds about 51.99 M in cash with (25.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| VistaGen Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Vistagen Therapeutics Stock Price Crosses Above 50-Day Moving Average - Heres Why - MarketBeat |
VistaGen Therapeutics Upcoming and Recent Events
Earnings reports are used by VistaGen Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 26th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
VistaGen Largest EPS Surprises
Earnings surprises can significantly impact VistaGen Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2021-11-10 | 2021-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2021-08-12 | 2021-06-30 | -0.05 | -0.04 | 0.01 | 20 |
VistaGen Therapeutics Environmental, Social, and Governance (ESG) Scores
VistaGen Therapeutics' ESG score is a quantitative measure that evaluates VistaGen Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of VistaGen Therapeutics' operations that may have significant financial implications and affect VistaGen Therapeutics' stock price as well as guide investors towards more socially responsible investments.
VistaGen Stock Institutional Investors
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 194.5 K | Bml Capital Management Llc | 2024-12-31 | 150 K | Two Sigma Investments Llc | 2024-12-31 | 137.3 K | Ubs Group Ag | 2024-12-31 | 132.3 K | Persistent Asset Partners Limited | 2024-12-31 | 121.7 K | Adar1 Capital Management Llc | 2024-12-31 | 121.5 K | Squarepoint Ops Llc | 2024-12-31 | 107.7 K | Advisorshares Investments, Llc | 2024-12-31 | 99.8 K | Blair William & Co | 2024-12-31 | 98.5 K | Tcg Crossover Management, Llc | 2024-12-31 | 2.7 M | Stempoint Capital Lp | 2024-12-31 | 2.3 M |
VistaGen Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 83.99 M.VistaGen Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.08) | (4.28) | |
| Return On Capital Employed | 8.95 | 14.87 | |
| Return On Assets | (4.08) | (4.28) | |
| Return On Equity | 8.98 | 12.43 |
Management Efficiency
VistaGen Therapeutics has return on total asset (ROA) of (0.2957) % which means that it has lost $0.2957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4628) %, meaning that it created substantial loss on money invested by shareholders. VistaGen Therapeutics' management efficiency ratios could be used to measure how well VistaGen Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, VistaGen Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 25th of March 2025, Return On Equity is likely to grow to 12.43, while Return On Tangible Assets are likely to drop (4.28). At this time, VistaGen Therapeutics' Net Tangible Assets are very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.05) | (0.05) | |
| Tangible Book Value Per Share | (0.05) | (0.05) | |
| Enterprise Value Over EBITDA | (4.54) | (4.76) | |
| Price Book Value Ratio | -28.7 K | -27.2 K | |
| Enterprise Value Multiple | (4.54) | (4.76) | |
| Price Fair Value | -28.7 K | -27.2 K | |
| Enterprise Value | 10 M | 9.5 M |
At VistaGen Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Technical Drivers
As of the 25th of March, VistaGen Therapeutics has the Risk Adjusted Performance of 0.0817, semi deviation of 2.8, and Coefficient Of Variation of 1217.93. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of VistaGen Therapeutics, as well as the relationship between them.VistaGen Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. VistaGen Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for VistaGen Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
VistaGen Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VistaGen Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VistaGen Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases VistaGen Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
VistaGen Therapeutics Outstanding Bonds
VistaGen Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. VistaGen Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most VistaGen bonds can be classified according to their maturity, which is the date when VistaGen Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US92840JAB52 Corp BondUS92840JAB52 | View | |
| VSTJET 7875 01 MAY 27 Corp BondUS92840JAD19 | View | |
| VST 5125 13 MAY 25 Corp BondUS92840VAL62 | View | |
| US92840VAH50 Corp BondUS92840VAH50 | View | |
| VISTRA OPERATIONS LLC Corp BondUS92840VAG77 | View | |
| Vistra Operations Co Corp BondUS92840VAF94 | View | |
| Vistra Operations Co Corp BondUS92840VAE20 | View |
VistaGen Therapeutics Predictive Daily Indicators
VistaGen Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of VistaGen Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 10336.35 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 2.86 | |||
| Day Typical Price | 2.84 | |||
| Price Action Indicator | (0.10) | |||
| Period Momentum Indicator | (0.10) |
VistaGen Therapeutics Corporate Filings
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 5th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 6th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
VistaGen Therapeutics Forecast Models
VistaGen Therapeutics' time-series forecasting models are one of many VistaGen Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary VistaGen Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About VistaGen Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how VistaGen Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling VistaGen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as VistaGen Therapeutics. By using and applying VistaGen Stock analysis, traders can create a robust methodology for identifying VistaGen entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (24.83) | (23.59) | |
| Operating Profit Margin | (27.93) | (26.53) | |
| Net Loss | (24.84) | (23.59) |
Current VistaGen Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. VistaGen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. VistaGen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 13.0 | Strong Buy | 4 | Odds |
Most VistaGen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand VistaGen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of VistaGen Therapeutics, talking to its executives and customers, or listening to VistaGen conference calls.
VistaGen Stock Analysis Indicators
VistaGen Therapeutics stock analysis indicators help investors evaluate how VistaGen Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading VistaGen Therapeutics shares will generate the highest return on investment. By understating and applying VistaGen Therapeutics stock analysis, traders can identify VistaGen Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 16.6 M | |
| Common Stock Shares Outstanding | 19.4 M | |
| Total Stockholder Equity | 114.3 M | |
| Tax Provision | 4000.00 | |
| Property Plant And Equipment Net | 2.3 M | |
| Cash And Short Term Investments | 119.2 M | |
| Cash | 119.2 M | |
| Accounts Payable | 1.5 M | |
| Net Debt | -117 M | |
| 50 Day M A | 2.8134 | |
| Total Current Liabilities | 5.1 M | |
| Other Operating Expenses | 34.1 M | |
| Non Current Assets Total | 3 M | |
| Non Currrent Assets Other | 726 K | |
| Stock Based Compensation | 2.2 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.